May 14, 2025
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
May 01, 2025
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Mar 12, 2025
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
Mar 11, 2025
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
Nov 13, 2024
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
Nov 12, 2024
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Sep 05, 2024
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Aug 26, 2024
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
Aug 15, 2024
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
Aug 13, 2024
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
Jul 11, 2024
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Jul 10, 2024
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
Mar 04, 2024
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Feb 21, 2024
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
Jan 27, 2021
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
Oct 29, 2020
Armata Pharmaceuticals Issues Letter to Shareholders
Oct 26, 2020
Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
Oct 15, 2020
Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections
Aug 13, 2020
Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update
Jun 17, 2020
Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections